- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06715345
Werkzaamheid en veiligheid van Novosis Putty voor degeneratieve lumbale aandoeningen
Door sponsor geïnitieerd klinisch onderzoek ter evaluatie van de werkzaamheid en veiligheid van Novosis Putty voor botfusie bij patiënten die posterieure instrumentatie en transforaminale lumbale interbodyfusie nodig hebben als gevolg van degeneratieve lumbale aandoeningen
This clinical study aims to evaluate the efficacy and safety of NOVOSIS PUTTY for bone fusion in patients requiring posterior instrumentation and transforaminal lumbar interbody fusion (TLIF) due to degenerative lumbar disease.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The Subject is a patient requiring posterior instrumentation and transforaminal lumbar interbody fusion (TLIF) due to degenerative lumbar disease.
This clinical study aims to compare and evaluate the efficacy and safety of three dose groups of NOVOSIS PUTTY for bone fusion compared to the autologous bone in patients requiring posterior instrumentation and TLIF in the single level between L2 and S1(L2-S1) due to degenerative lumbar disease.
- Control Group (n=12): Local autologous bone
- Experimental Group 1 (n=12): Dose 1 (BMP2_1mg)
- Experimental Group 2 (n=12): Dose 2 (BMP2_2mg)
- Experimental Group 3 (n=12): Dose 3 (BMP2_3mg)
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Seoul, Zuid -Korea, 03312
- The Catholic University of Korea, Eunpyeong St. Mary's Hospital
-
Seoul, Zuid -Korea, 06591
- The Catholic University of Korea, Seoul ST. Mary's Hospital
-
Seoul, Zuid -Korea, 05505
- Asan medical center
-
Seoul, Zuid -Korea
- Severance hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Adult aged ≥ 22 to ≤ 80 years
- Subjects whose skeletal maturation are confirmed by showing the result of Risser stage 5 in Risser classification, the Plain Radiography
- Subjects diagnosed with disc degeneration in the single level (L2-S1) lumbar spine along with spondylolisthesis of Meyerding grade 1 (degree of translocation: 0- <25%) or 2 (degree of translocation: 25- <50%) based on the results of radiological examination (CT, MRI, X-ray).
- Subjects with an ODI (Oswestry Disability Index) score of ≥ 35/100 at screening
- Subjects who were treated with non surgical treatment/therapy for at least 3 months, but were judged to have failed treatment by the investigator
- Subjects who are willing to participate in the study, comply with treatment and procedures, and visit the hospital for all observational evaluations
- Subjects who voluntarily signed the informed consent form after hearing the explanation on objectives and methods of this study
Exclusion Criteria:
- Subjects who have a history of medical device application (spinal instrumentation, for example, anterior disc replacement, interspinous device) to the target site or interbody fusion
- Subjects who are considered that the symptoms occurring in the lumbar region are not occurred by disc degeneration
- Subjects with active malignancy
- Subjects with a documented history of drug abuse (e.g., psychotropic drugs including narcotic analgesics and drugs with high dependence such as alcohol) within the last 6 months
- Subjects with a history of endocrine or metabolic disorders known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehler Danlos disease, or osteogenesis imperfecta)
- Subjects with BMI ≥ 35
- Subjects with spondylolis thesis/retrolisthesis with ≥ Grade 3 in the target level
- Subjects with a local acute infection at the current surgical site or active systemic infection (e.g., viral infections such as AIDS, HIV or hepatitis)
- Subjects with a history of metabolic or endocrine diseases known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers Danlos disease, osteogenesis imperfecta, fibrous dysplasia, etc.)
- Subjects with osteoporosis with a mean lumbar spine T-score of ≤ 2.5 on the DEXA bone density test and with a history of osteoporotic fractures (wrist fractures, femur fractures, lumbar spine fractures, etc.)
- Subjects who need to administer drugs that inhibit bone metabolism within 2 weeks after surgery, or Subjects who need to receive post operative drugs that are expected to interfere with bone fusion, such as steroids
- Subjects who smoke ≥ 20 cigarettes a day
- Subjects with autoimmune disease
- Subjects who were exposed to rhBMP 2 in the past
- Subjects who require to get fusion of two or more vertebral levels
- Subjects who have a pseudoarthrosis after previous fusion
- Subjects who had a history of at least one non fusion spinal surgery on the level to be operated
- Subjects who are considered to have a disease that hinders the accurate evaluation (e.g., neuromuscular disease, serious psychiatric disease) at the discretion of the investigator
- Subjects who are pregnant at screening or who are planning to become pregnant during the study participation period
- Subjects who are currently lactating or who are planning to lactate during the study
- Subjects who participated in studies for other drugs, biologics, or medical devices within 6 months from the date of surgery
- Subjects who are in a difficult situation to comply with study related matters
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Geen tussenkomst: Control Group
Local autologous bone |
|
|
Experimenteel: Experimental Group 1
Dose 1(BMP2_1mg) |
NOVOSIS PUTTY is a product composed of recombinant human bone morphogenetic protein-2(BMP2) and β-tricalcium phosphate/hydrogel complex. |
|
Experimenteel: Experimental Group 2
Dose 2(BMP2_2mg) |
NOVOSIS PUTTY is a product composed of recombinant human bone morphogenetic protein-2(BMP2) and β-tricalcium phosphate/hydrogel complex. |
|
Experimenteel: Experimental Group 3
Dose 3(BMP2_3mg) |
NOVOSIS PUTTY is a product composed of recombinant human bone morphogenetic protein-2(BMP2) and β-tricalcium phosphate/hydrogel complex. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall bone fusion rate
Tijdsspanne: 12 months after surgery
|
Meet the definition of bone fusion based on CT and the definition of bone fusion based on X-ray simultaneously. |
12 months after surgery
|
|
Overall fusion success rate
Tijdsspanne: 12 months after surgery
|
Meet all of the following conditions:
|
12 months after surgery
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall fusion success rate
Tijdsspanne: 6 and 24 months after surgery
|
Meet all of the following conditions:
|
6 and 24 months after surgery
|
|
Bone fusion rate
Tijdsspanne: 6, 12, and 24 months after surgery
|
Bone fusion rate based on CT, X-ray |
6, 12, and 24 months after surgery
|
|
Oswestry Disability Index(ODI)
Tijdsspanne: 6 weeks, 3, 6, 12, and 24 months after surgery
|
Evaluate Oswestry Disability Index(ODI) score/ lowest 0(best) to highest 50(worst) |
6 weeks, 3, 6, 12, and 24 months after surgery
|
|
SF-12 scores (general condition test)
Tijdsspanne: 6 weeks, 3, 6, 12, and 24 months after surgery
|
Evaluate SF-12 scores / lowest 0(worst) to highest 100(best) |
6 weeks, 3, 6, 12, and 24 months after surgery
|
|
Numerical Rating Scale (NRS)
Tijdsspanne: 6 weeks, 3, 6, 12, and 24 months after surgery
|
Evaluate Numerical Rating Scale (NRS) scores / lowest 0(best) to highest 30(worst) |
6 weeks, 3, 6, 12, and 24 months after surgery
|
|
Neurological Symptoms
Tijdsspanne: 6 weeks, 3, 6, 12, and 24 months after surgery
|
Evaluate Neurological Symptoms test/ check among the 3 questions(Worsened/ Constent/Improved) best is imporved, worst is worsened |
6 weeks, 3, 6, 12, and 24 months after surgery
|
|
Satisfaction rate
Tijdsspanne: 6 weeks, 3, 6, 12, and 24 months after surgery
|
Evaluate Satisfaction rate score / lowest 0(worst) to highest 3(best) |
6 weeks, 3, 6, 12, and 24 months after surgery
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie stoel: Jumi Han, CGBio Inc.
Publicaties en nuttige links
Algemene publicaties
- Mobbs RJ, Phan K, Malham G, Seex K, Rao PJ. Lumbar interbody fusion: techniques, indications and comparison of interbody fusion options including PLIF, TLIF, MI-TLIF, OLIF/ATP, LLIF and ALIF. J Spine Surg. 2015 Dec;1(1):2-18. doi: 10.3978/j.issn.2414-469X.2015.10.05.
- GJESSING MH. Osteoplastic anterior fusion of the lower lumbar spine in spondylolisthesis, localized spondylosis, and tuberculous spondylitis. Acta Orthop Scand. 1951;20(3):200-13. doi: 10.3109/17453675108991168. No abstract available.
- Smith JS, Fu KM, Polly DW Jr, Sansur CA, Berven SH, Broadstone PA, Choma TJ, Goytan MJ, Noordeen HH, Knapp DR Jr, Hart RA, Donaldson WF 3rd, Perra JH, Boachie-Adjei O, Shaffrey CI. Complication rates of three common spine procedures and rates of thromboembolism following spine surgery based on 108,419 procedures: a report from the Scoliosis Research Society Morbidity and Mortality Committee. Spine (Phila Pa 1976). 2010 Nov 15;35(24):2140-9. doi: 10.1097/BRS.0b013e3181cbc8e7.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- B2201
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .